| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9314 | Pemetrexed (Teva) | Pemetrexed (Teva) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Dec 21, 2022 | In Use | ||
| Q5130 | Pegfilgrastim-pbbk | Fylnetra | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | Mar 17, 2023 | In Use | ||
| Q5126 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Nov 28, 2022 | In Use | ||
| Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
| C9147 | Tremelimumab-actl | Imjudo | 1mg | Immunotherapy | Monoclonal Antibody | CTLA-4 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| C9098 | Ciltacabtagene autoleucel | CARVYKTI | up to 100 million | Immunotherapy | CAR-T | No | 2022 | Mar 25, 2022 | Sep 27, 2022 | No Longer Used | ||
| J9059 | Bendamustine (Baxter) | Bendamustine (Baxter) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | Dec 17, 2024 | No Longer Used | |
| J9056 | Bendamustine hydrochloride (Vivimusta) | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
| C9095 | Tebentafusp-tebn | Kimmtrak | 1mcg | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | No | 2022 | Mar 25, 2022 | Sep 27, 2022 | No Longer Used | |
| Q5125 | Filgrastim | Releuko | 1mcg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | Sep 27, 2022 | In Use | ||
| C9148 | Teclistamab-cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| J9380 | Teclistamab cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Jul 11, 2023 | In Use | ||
| C9146 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| Q2056 | Ciltacabtagene autoleucel | CARVYKTI | up to 100 million | Immunotherapy | CAR-T | No | 2022 | Sep 27, 2022 | In Use | |||
| Adagrasib | Krazati | 200mg | Immunotherapy | RAS Inhibitor | KrAS G12C | Yes | 2022 | In Use | ||||
| J1954 | Leuprolide acetate for depot suspension (lutrate depot) | Lutrate Depot | 7.5mg | Hormonal Therapy | GnRH Agonist | No | 2022 | Apr 1, 2023 | In Use | |||
| J9063 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Jul 11, 2023 | In Use | ||
| C9142 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Sep 27, 2022 | Dec 21, 2022 | No Longer Used | |
| Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
| J9051 | Bortezomib (Maia) | Bortezomib | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | Yes | 2022 | Aug 28, 2023 | In Use | ||
| J9058 | Bendamustine (Apotex) | Bendamustine (Apotex) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2023 | Jul 11, 2023 | Sep 14, 2024 | No Longer Used | |
| Nirogacestat | Ogsiveo | 50mg, 100mg, 150mg | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Yes | 2023 | In Use | ||||
| NA | Elacestrant | Orserdu | Multiple | Hormonal Therapy | Estrogen Receptor Antagonist | ERɑ | Yes | 2023 | In Use | |||
| Repotrectinib | Augtyro | 40mg, 160mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Yes | 2023 | In Use | ||||
| J9324 | Pemetrexed disodium | Pemrydi-rtu | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2023 | Dec 7, 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home